Literature DB >> 9493270

Hepatitis C virus NS3 RNA helicase domain with a bound oligonucleotide: the crystal structure provides insights into the mode of unwinding.

J L Kim1, K A Morgenstern, J P Griffith, M D Dwyer, J A Thomson, M A Murcko, C Lin, P R Caron.   

Abstract

BACKGROUND: Hepatitis C virus (HCV) represents a major health concern as it is responsible for a significant number of hepatitis cases worldwide. Much research has focused on the replicative enzymes of HCV as possible targets for more effective therapeutic agents. HCV NS3 helicase may provide one such suitable target. Helicases are enzymes which can unwind double-stranded regions of DNA or RNA in an ATP-dependent reaction. The structures of several helicases have been published but the structural details as to how ATP binding and hydrolysis are coupled to RNA unwinding are unknown.
RESULTS: The structure of the HCV NS3 RNA helicase domain complexed with a single-stranded DNA oligonucleotide has been solved to 2.2 A resolution. The protein consists of three structural domains with the oligonucleotide lying in a groove between the first two domains and the third. The first two domains have an adenylate kinase like fold, including a phosphate-binding loop in the first domain.
CONCLUSIONS: HCV NS3 helicase is a member of a superfamily of helicases, termed superfamily II. Residues of NS3 helicase which are conserved among superfamily II helicases line an interdomain cleft between the first two domains. The oligonucleotide binds in an orthogonal binding site and contacts relatively few conserved residues. There are no strong sequence-specific interactions with the oligonucleotide bases.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9493270     DOI: 10.1016/s0969-2126(98)00010-0

Source DB:  PubMed          Journal:  Structure        ISSN: 0969-2126            Impact factor:   5.006


  221 in total

1.  Crystal structure of the DNA nucleotide excision repair enzyme UvrB from Thermus thermophilus.

Authors:  M Machius; L Henry; M Palnitkar; J Deisenhofer
Journal:  Proc Natl Acad Sci U S A       Date:  1999-10-12       Impact factor: 11.205

2.  Crystallographic structure of the amino terminal domain of yeast initiation factor 4A, a representative DEAD-box RNA helicase.

Authors:  E R Johnson; D B McKay
Journal:  RNA       Date:  1999-12       Impact factor: 4.942

Review 3.  Perspectives for the treatment of infections with Flaviviridae.

Authors:  P Leyssen; E De Clercq; J Neyts
Journal:  Clin Microbiol Rev       Date:  2000-01       Impact factor: 26.132

4.  Crystal structure of a DEAD box protein from the hyperthermophile Methanococcus jannaschii.

Authors:  R M Story; H Li; J N Abelson
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-13       Impact factor: 11.205

5.  The 100-kda U5 snRNP protein (hPrp28p) contacts the 5' splice site through its ATPase site.

Authors:  N Ismaïli; M Sha; E H Gustafson; M M Konarska
Journal:  RNA       Date:  2001-02       Impact factor: 4.942

6.  Cross-talk between catalytic and regulatory elements in a DEAD motor domain is essential for SecA function.

Authors:  G Sianidis; S Karamanou; E Vrontou; K Boulias; K Repanas; N Kyrpides; A S Politou; A Economou
Journal:  EMBO J       Date:  2001-03-01       Impact factor: 11.598

7.  Mutations that affect dimer formation and helicase activity of the hepatitis C virus helicase.

Authors:  Y L Khu; E Koh; S P Lim; Y H Tan; S Brenner; S G Lim; W J Hong; P Y Goh
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

8.  Characterization and mutational analysis of yeast Dbp8p, a putative RNA helicase involved in ribosome biogenesis.

Authors:  M C Daugeron; P Linder
Journal:  Nucleic Acids Res       Date:  2001-03-01       Impact factor: 16.971

9.  Crystal structure of yeast initiation factor 4A, a DEAD-box RNA helicase.

Authors:  J M Caruthers; E R Johnson; D B McKay
Journal:  Proc Natl Acad Sci U S A       Date:  2000-11-21       Impact factor: 11.205

10.  RNA helicase dynamics in pre-mRNA splicing.

Authors:  B Schwer; T Meszaros
Journal:  EMBO J       Date:  2000-12-01       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.